



HAL
open science

Antibacterial Peptides

Jean-Marc Sabatier

► **To cite this version:**

Jean-Marc Sabatier. Antibacterial Peptides. *Antibiotics*, 2020, 9 (4), pp.142. <10.3390/antibiotics9040142>. <hal-03357872>

HAL Id: hal-03357872

<https://amu.hal.science/hal-03357872v1>

Submitted on 15 Jun 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY 4.0 - Attribution - International License

Editorial

Antibacterial Peptides

Jean-Marc Sabatier 

Université Aix-Marseille, Institut de Neurophysiopathologie (INP), UMR 7051, 13005 Marseille, France; sabatier.jm1@libertysurf.fr

Received: 24 March 2020; Accepted: 25 March 2020; Published: 26 March 2020



As natural host defense compounds produced by numerous prokaryotic and eukaryotic life forms, antimicrobial peptides (AMPs) are now emerging as solid candidate chemotherapeutic drugs to fight against the various types of pathogenic Gram-positive and Gram-negative bacteria, especially those resistant to current antibiotics. This special issue of *'Antibiotics'* has been focused on the various aspects of such AMPs, from their discovery to the structural and functional characterization thereof. The authors of articles published in this special issue (10 articles, including a review article) are thanked for their important contributions to this essential field of applied research, by allowing a more 'in-depth' knowledge on the AMPs.

A first original article by Lattorff deals with the social environment-dependency of two lysozyme genes expression in bumblebees (lysozyme being part of the antimicrobial response of these insects), as well as its tissue specificity [1]. Boix-Lemonche and collaborators [2] developed an interesting fast fluorescence-based microplate assay to examine the effects of AMPs on membranes of whole Gram-positive bacteria. Apart from providing a tool to investigate the mode of action of antibacterials on Gram-positive bacteria, this approach might be particularly useful to screen novel AMPs. Other key studies by Flórez-Castillo [3], Della Pelle [4], Paquette [5], and their collaborators have reported on the structural properties, molecular docking simulation experiments, and/or antibacterial potential of specific antimicrobials, i.e., Ib-M6, Antarctic fish (transcriptome-derived) Trematocine, and *E. coli* antimicrobial molecule, respectively. The data presented are of great interest in the field and may help the design of potent candidate AMPs. Shelenkov and coworkers [6], by performing a computer-based search for potential AMPs in 1267 plant transcriptomes (50–150 peptides were highlighted in each transcriptome), also provided us with a large number of candidate AMPs to examine. By peptide/protein engineering, some 'optimized' chemical structures of AMPs can be selected and chemically produced, an approach used by Liscano et al. with Alyteserin 1c [7] and Woodburn et al. [8]. Such antibacterial compounds were shown to possess distinct potencies and/or selectivities toward Gram-positive and Gram-negative bacteria and may lead to newly designed AMP(s) with potent activity on antibiotic-resistant bacterial strain(s) [8]. Importantly, Cheng and collaborators [9] found that a scorpion venom defensin (BmKDfsin3, a host defense antimicrobial peptide) was able to dose-dependently inhibit Hepatitis C viral infection of target cells via suppression of the p38 mitogen-activated protein kinase (MAPK) activation. Finally, an outstanding up-to-date review article by Gray and Wenzel [10] on the marketed cyclic lipopeptide antibiotic Daptomycin is provided in this special issue on 'Antimicrobial peptides'. I strongly believe that the scientists and clinicians working in the field will find the special issue of particular interest and a real source of inspiration.

Conflicts of Interest: The author declares no conflict of interest.

References

1. Lattorff, H.M. Tissue specificity in social context-dependent lysozyme expression in bumblebees. *Antibiotics* **2020**, *9*, 130. [[CrossRef](#)]
2. Boix-Lemonche, G.; Lekka, M.; Skerlavaj, B. A rapid fluorescence-based microplate assay to investigate the interaction of membrane active antimicrobial peptides with whole Gram-positive bacteria. *Antibiotics* **2020**, *9*, 92. [[CrossRef](#)] [[PubMed](#)]
3. Flórez-Castillo, J.M.; Rondón-Villareal, P.; Roperro-Vega, J.L.; Mendoza-Espinel, S.Y.; Moreno-Amézquita, J.A.; Méndez-Jaimes, K.D.; Farfán-García, A.E.; Gómez-Rangel, S.Y.; Gómez-Duarte, O.G. Ib-M6 Antimicrobial peptide: Antibacterial activity against clinical isolates of *Escherichia coli* and molecular docking. *Antibiotics* **2020**, *9*, 79. [[CrossRef](#)] [[PubMed](#)]
4. Della Pelle, G.; Pera, G.; Belardinelli, M.C.; Gerdol, M.; Felli, M.; Crognale, S.; Scapigliati, G.; Ceccacci, F.; Buonocore, F.; Porcelli, F. Trematocine, a novel antimicrobial peptide from the antarctic fish *Trematomus bernacchii*: Identification and biological activity. *Antibiotics* **2020**, *9*, 66. [[CrossRef](#)] [[PubMed](#)]
5. Paquette, S.J.; Reuter, T. Properties of an antimicrobial molecule produced by an *Escherichia coli* champion. *Antibiotics* **2020**, *9*, 6. [[CrossRef](#)] [[PubMed](#)]
6. Shelenkov, A.; Slavokhotova, A.; Odintsova, T. Predicting antimicrobial and other cysteine-rich peptides in 1267 plant transcriptomes. *Antibiotics* **2020**, *9*, 60. [[CrossRef](#)] [[PubMed](#)]
7. Liscano, Y.; Salamanca, C.H.; Vargas, L.; Cantor, S.; Laverde-Rojas, V.; Oñate-Garzón, J. Increases in hydrophilicity and charge on the polar face of Alyteserin 1c helix change its selectivity towards Gram-positive bacteria. *Antibiotics* **2019**, *8*, 238. [[CrossRef](#)] [[PubMed](#)]
8. Woodburn, K.W.; Jaynes, J.; Clemens, L.E. Designed antimicrobial peptides for topical treatment of antibiotic resistant *Acne vulgaris*. *Antibiotics* **2020**, *9*, 23. [[CrossRef](#)] [[PubMed](#)]
9. Cheng, Y.; Sun, F.; Li, S.; Gao, M.; Wang, L.; Sarhan, M.; Abdel-Rahman, M.A.; Li, W.; Kwok, H.F.; Wu, Y.; et al. Inhibitory activity of a scorpion defensin BmKDfsin3 against Hepatitis C virus. *Antibiotics* **2020**, *9*, 33. [[CrossRef](#)] [[PubMed](#)]
10. Gray, D.A.; Wenzel, M. More than a pore: A current perspective on the in vivo mode of action of the lipopeptide antibiotic Daptomycin. *Antibiotics* **2020**, *9*, 17. [[CrossRef](#)] [[PubMed](#)]



© 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<http://creativecommons.org/licenses/by/4.0/>).